We propose that for oncology drugs that demonstrate "exceptional activity" in Phase 1 or Phase 2 trials and receive accelerated/conditional approval and/or Breakthrough Therapy Designation, and for certain expanded indications, regulatory authorities should consider accepting data from prospectively-agreed pragmatic randomized clinical trials to grant full regulatory approval.
from Cancer via ola Kala on Inoreader http://ift.tt/25xyN9B
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου